Carbidopa and levodopa orally disintegrating tablets are indicated in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Carbidopa and levodopa orally disintegrating tablets are indicated in these conditions to per...
Just prior to administration, GENTLY remove the tablet from the bottle with dry hands. IMMEDIATELY place the carbidopa and levodopa orally disintegrating tablet on top of the tongue where it will dissolve in seconds, then swallow with saliva. Administration with liquid is not necessary. The optimum daily dosage of carbidopa and levodopa orally disintegrating tablets must be determined by careful titration in each ...
Carbidopa and levodopa orally disintegrating tablets, USP are a combination of carbidopa and levodopa for the treatment of Parkinson's disease and syndrome. Carbidopa and levodopa orally disintegrating tablets are an orally administered formulation of carbidopa and levodopa which rapidly disintegrates on the tongue and does not require water to aid dissolution or swallowing.
Carbidopa, USP, an inhibitor of aromatic amino acid decarboxylation, is a white to creamy white powder, slightly soluble in water, with a molecular weight of 244.2. It is designated chemically as (-)-L-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid monohydrate. Its molecular formula is C10H14N2O4•H2O, and its structural formula is:
Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.2.
Levodopa, USP, an aromatic amino acid, is a white to off-white crystalline powder, slightly soluble in water, with a molecular weight of 197.2. It is designated chemically as (-)-3-(3,4-Dihydroxyphenyl)-L-alanine. Its molecular formula is C9H11NO4, and its structural formula is:
Carbidopa and levodopa orally disintegrating tablets, USP are supplied as tablets in three strengths:
Carbidopa and Levodopa Orally Disintegrating Tablets 10 mg /100 mg, containing 10 mg of carbidopa and 100 mg of levodopa.
Carbidopa and Levodopa Orally Disintegrating Tablets 25 mg/100 mg, containing 25 mg of carbidopa and 100 mg of levodopa.
Carbidopa and Levodopa Orally Disintegrating Tablets 25 mg/250 mg, containing 25 mg of carbidopa and 250 mg of levodopa.
Inactive ingredients are aspartame, crospovidone, mannitol, microcrystalline cellulose, peppermint flavor, silica, sodium stearyl fumarate and sorbitol. In addition, the 25 mg/100 mg tablets contain FD&C Blue No. 1 Aluminum Lake and the 10 mg/100 mg and 25 mg/250 mg tablets contain D&C Yellow No. 10 Aluminum Lake and FD&C Blue No. 1 Aluminum Lake.
Parkinson's disease is a progressive, neurodegenerative disorder of the extrapyramidal nervous system affecting the mobility and control of the skeletal muscular system. Its characteristic features include resting tremor, rigidity, and bradykinetic movements. Symptomatic treatments, such as levodopa therapies, may permit the patient better mobility.
Current evidence indicates that symptoms of Parkinson's disease are related to depletion of dopamine in the corpus striatum. Administration of dopamine is ineffective in the treatment of Parkinson's disease apparently because it does not cross the blood-brain barrier. However, levodopa, the metabolic precursor of dopamine, does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa relieves symptoms of Parkinson's disease.
When levodopa is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. For this reason, large doses of levodopa are required for adequate therapeutic effect and these may often be accompanied by nausea and other adverse reactions, some of which are attributable to dopamine formed in extracerebral tissues.
Since levodopa competes with certain amino acids for transport across the gut wall, the absorption of levodopa may be impaired in some patients on a high protein diet.
Carbidopa inhibits decarboxylation of peripheral levodopa. It does not cross the blood-brain barrier and does not affect the metabolism of levodopa within the central nervous system.
The incidence of levodopa-induced nausea and vomiting is less with carbidopa and levodopa than with levodopa. In many patients, this reduction in nausea and vomiting will permit more rapid dosage titration.
Since its decarboxylase inhibiting activity is limited to extracerebral tissues, administration of carbidopa with levodopa makes more levodopa available for transport to the brain.
Carbidopa reduces the amount of levodopa required to produce a given response by about 75% and, when administered with levodopa, increases both plasma levels and the plasma half-life of levodopa, and decreases plasma and urinary dopamine and homovanillic acid.
The plasma half-life of levodopa is about 50 minutes, without carbidopa. When carbidopa and levodopa are administered together, the half-life of levodopa is increased to about 1.5 hours. At steady-state, the bioavailability of carbidopa from carbidopa and levodopa tablets is approximately 99% relative to the concomitant administration of carbidopa and levodopa.
In clinical pharmacologic studies, simultaneous administration of carbidopa and levodopa produced greater urinary excretion of levodopa in proportion to the excretion of dopamine than administration of the two drugs at separate times.
Pyridoxine hydrochloride (vitamin B6), in oral doses of 10 mg to 25 mg, may reverse the effects of levodopa by increasing the rate of aromatic amino acid decarboxylation. Carbidopa inhibits this action of pyridoxine; therefore, carbidopa and levodopa orally disintegrating tablets can be given to patients receiving supplemental pyridoxine (vitamin B6).
Carbidopa and levodopa orally disintegrating tablets are indicated in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Carbidopa and levodopa orally disintegrating tablets are indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin B6).
In some patients, a somewhat smoother antiparkinsonian effect results from therapy with carbidopa and levodopa than with levodopa. However, patients with markedly irregular ("on-off") responses to levodopa have not been shown to benefit from carbidopa and levodopa therapy.
Although the administration of carbidopa permits control of parkinsonism and Parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa.
Certain patients who responded poorly to levodopa have improved when carbidopa and levodopa was substituted. This is most likely due to decreased peripheral decarboxylation of levodopa which results from administration of carbidopa rather than to a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa in parkinsonian syndromes.
In considering whether to give carbidopa and levodopa orally disintegrating tablets to patients already on levodopa who have nausea and/or vomiting, the practitioner should be aware that, while many patients may be expected to improve, some do not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa and levodopa with levodopa, about half of the patients with nausea and/or vomiting on levodopa improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial.
Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with carbidopa and levodopa orally disintegrating tablets. These inhibitors must be discontinued at least 2 weeks prior to initiating therapy with carbidopa and levodopa orally disintegrating tablets. Carbidopa and levodopa orally disintegrating tablets may be administered concomitantly with the manufacturer's recommended dose of an MAO inhibitor with selectivity for MAO type B (e.g., selegiline HCl) (see PRECAUTIONS: Drug Interactions).
Carbidopa and levodopa orally disintegrating tablets are contraindicated in patients with known hypersensitivity to any component of this drug, and in patients with narrow-angle glaucoma.
Because levodopa may activate a malignant melanoma, carbidopa and levodopa orally disintegrating tablets should not be used in patients with suspicious, undiagnosed skin lesions or a history of melanoma.
When carbidopa and levodopa orally disintegrating tablets are to be given to patients who are being treated with levodopa, levodopa must be discontinued at least 12 hours before therapy with carbidopa and levodopa orally disintegrating tablets are started. In order to reduce adverse reactions, it is necessary to individualize therapy. See DOSAGE AND ADMINISTRATION section before initiating therapy.
The addition of carbidopa with levodopa in the form of carbidopa and levodopa orally disintegrating tablets reduces the peripheral effects (nausea, vomiting) due to decarboxylation of levodopa; however, carbidopa does not decrease the adverse reactions due to the central effects of levodopa. Because carbidopa permits more levodopa to reach the brain and more dopamine to be formed, certain adverse CNS effects, e.g., dyskinesias (involuntary movements), may occur at lower dosages and sooner with carbidopa and levodopa orally disintegrating tablets than with levodopa alone.
Levodopa alone, as well as carbidopa and levodopa orally disintegrating tablets, is associated with dyskinesias. The occurrence of dyskinesias may require dosage reduction.
As with levodopa, carbidopa and levodopa orally disintegrating tablets may cause mental disturbances. These reactions are thought to be due to increased brain dopamine following administration of levodopa. All patients should be observed carefully for the development of depression with concomitant suicidal tendencies. Patients with past or current psychoses should be treated with caution.
Carbidopa and levodopa orally disintegrating tablets should be administered cautiously to patients with severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease.
As with levodopa, care should be exercised in administering carbidopa and levodopa orally disintegrating tablets to patients with a history of myocardial infarction who have residual atrial, nodal, or ventricular arrhythmias. In such patients, cardiac function should be monitored with particular care during the period of initial dosage adjustment, in a facility with provisions for intensive cardiac care.
As with levodopa, treatment with carbidopa and levodopa orally disintegrating tablets may increase the possibility of upper gastrointestinal hemorrhage in patients with a history of peptic ulcer.
Sporadic cases of a symptom complex resembling NMS have been reported in association with dose reductions or withdrawal of therapy with carbidopa and levodopa. Therefore, patients should be observed carefully when the dosage of carbidopa and levodopa orally disintegrating tablets is reduced abruptly or discontinued, especially if the patient is receiving neuroleptics.
NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia. Neurological findings, including muscle rigidity, involuntary movements, altered consciousness, mental status changes; other disturbances, such as autonomic dysfunction, tachycardia, tachypnea, sweating, hyper- or hypotension; laboratory findings, such as creatine phosphokinase elevation, leukocytosis, myoglobinuria, and increased serum myoglobin have been reported.
The early diagnosis of this condition is important for the appropriate management of these patients. Considering NMS as a possible diagnosis and ruling out other acute illnesses (e.g., pneumonia, systemic infection, etc.) is essential. This may be especially complex if the clinical presentation includes both serious medical illness and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology.
The management of NMS should include: 1) intensive symptomatic treatment and medical monitoring and 2) treatment of any concomitant serious medical problems for which specific treatments are available. Dopamine agonists, such as bromocriptine, and muscle relaxants, such as dantrolene, are often used in the treatment of NMS, however, their effectiveness has not been demonstrated in controlled studies.
As with levodopa, periodic evaluations of hepatic, hematopoietic, cardiovascular, and renal function are recommended during extended therapy.
Patients with chronic wide-angle glaucoma may be treated cautiously with carbidopa and levodopa orally disintegrating tablets provided the intraocular pressure is well controlled and the patient is monitored carefully for changes in intraocular pressure during therapy.
Phenylketonuric patients should be informed that carbidopa and levodopa orally disintegrating tablets contain phenylalanine 3.37 mg per 10 mg/100 mg orally disintegrating tablet, 3.37 mg per 25 mg/100 mg orally disintegrating tablet, and 8.42 mg per 25 mg/250 mg orally disintegrating tablet.
Patients should be instructed not to remove carbidopa and levodopa orally disintegrating tablets from the bottle until just prior to dosing. With dry hands, the tablet should be gently removed and immediately placed on the tongue to dissolve and be swallowed with the saliva.
The patient should be informed that carbidopa and levodopa orally disintegrating tablets are an immediate-release formulation of carbidopa and levodopa that is designed to begin release of ingredients within 30 minutes. It is important that carbidopa and levodopa orally disintegrating tablets be taken at regular intervals according to the schedule outlined by the physician. The patient should be cautioned not to change the prescribed dosage regimen and not to add any additional antiparkinson medications, including other carbidopa and levodopa preparations, without first consulting the physician.
Patients should be advised that sometimes a "wearing-off" effect may occur at the end of the dosing interval. The physician should be notified if such response poses a problem to lifestyle.
Patients should be advised that occasionally, dark color (red, brown, or black) may appear in saliva, urine, or sweat after ingestion of carbidopa and levodopa orally disintegrating tablets. Although the color appears to be clinically insignificant, garments may become discolored.
The patient should be advised that a change in diet to foods that are high in protein may delay the absorption of levodopa and may reduce the amount taken up in the circulation. Excessive acidity also delays stomach emptying, thus delaying the absorption of levodopa. Iron salts (such as in multi-vitamin tablets) may also reduce the amount of levodopa available to the body. The above factors may reduce the clinical effectiveness of the levodopa or carbidopa and levodopa therapy.
NOTE: The suggested advice to patients being treated with carbidopa and levodopa orally disintegrating tablets is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.
Abnormalities in laboratory tests may include elevations of liver function tests such as alkaline phosphatase, SGOT (AST), SGPT (ALT), lactic dehydrogenase, and bilirubin. Abnormalities in blood urea nitrogen and positive Coombs test have also been reported. Commonly, levels of blood urea nitrogen, creatinine, and uric acid are lower during administration of carbidopa and levodopa than with levodopa.
Carbidopa and levodopa may cause a false-positive reaction for urinary ketone bodies when a test tape is used for determination of ketonuria. This reaction will not be altered by boiling the urine specimen. False-negative tests may result with the use of glucose-oxidase methods of testing for glucosuria.
Cases of falsely diagnosed pheochromocytoma in patients on carbidopa and levodopa therapy have been reported very rarely. Caution should be exercised when interpreting the plasma and urine levels of catecholamines and their metabolites in patients on levodopa or carbidopa and levodopa therapy.
Caution should be exercised when the following drugs are administered concomitantly with carbidopa and levodopa orally disintegrating tablets.
Symptomatic postural hypotension has occurred when carbidopa and levodopa was added to the treatment of a patient receiving antihypertensive drugs. Therefore, when therapy with carbidopa and levodopa orally disintegrating tablets is started, dosage adjustment of the antihypertensive drug may be required.
For patients receiving MAO inhibitors (Type A or B), see CONTRAINDICATIONS. Concomitant therapy with selegiline and carbidopa and levodopa may be associated with severe orthostatic hypotension not attributable to carbidopa and levodopa alone (see CONTRAINDICATIONS).
There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa and levodopa.
Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa. In addition, the beneficial effects of levodopa in Parkinson's disease have been reported to be reversed by phenytoin and papaverine. Patients taking these drugs with carbidopa and levodopa orally disintegrating tablets should be carefully observed for loss of therapeutic response. Iron salts may reduce the bioavailability of levodopa and carbidopa. The clinical relevance is unclear.
Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.
In a 2-year bioassay of carbidopa and levodopa, no evidence of carcinogenicity was found in rats receiving doses of approximately 2 times the maximum daily human dose of carbidopa and 4 times the maximum daily human dose of levodopa.
In reproduction studies with carbidopa and levodopa, no effects on fertility were found in rats receiving doses of approximately 2 times the maximum daily human dose of carbidopa and four times the maximum daily human dose of levodopa.
No teratogenic effects were observed in a study in mice receiving up to 20 times the maximum recommended human dose of carbidopa and levodopa. There was a decrease in the number of live pups delivered by rats receiving approximately 2 times the maximum recommended human dose of carbidopa and approximately 5 times the maximum recommended human dose of levodopa during organogenesis. Carbidopa and levodopa caused both visceral and skeletal malformations in rabbits at all doses and ratios of carbidopa/levodopa tested, which ranged from 10 times/5 times the maximum recommended human dose of carbidopa/levodopa to 20 times/10 times the maximum recommended human dose of carbidopa/levodopa.
There are no adequate or well controlled studies in pregnant women. It has been reported from individual cases that levodopa crosses the human placental barrier, enters the fetus, and is metabolized. Carbidopa concentrations in fetal tissue appeared to be minimal. Use of carbidopa and levodopa orally disintegrating tablets in women of childbearing potential requires that the anticipated benefits of the drug be weighed against possible hazards to mother and child.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when carbidopa and levodopa orally disintegrating tablets are administered to a nursing woman.
Safety and effectiveness in pediatric patients have not been established. Use of the drug in patients below the age of 18 is not recommended.
The most common adverse reactions reported with carbidopa and levodopa therapy have included dyskinesias, such as choreiform, dystonic, and other involuntary movements and nausea.
The following other adverse reactions have been reported with carbidopa and levodopa:
Body as a Whole: chest pain, asthenia
Cardiovascular: cardiac irregularities, hypotension, orthostatic effects including orthostatic hypotension, hypertension, syncope, phlebitis, palpitation
Gastrointestinal: dark saliva, gastrointestinal bleeding, development of duodenal ulcer, anorexia, vomiting, diarrhea, constipation, dyspepsia, dry mouth, taste alterations
Hematologic: agranulocytosis, hemolytic and nonhemolytic anemia, thrombocytopenia, leukopenia
Hypersensitivity: angioedema, urticaria, pruritus, Henoch-Schonlein purpura, bullous lesions (including pemphigus-like reactions)
Musculoskeletal: back pain, shoulder pain, muscle cramps
Nervous System/Psychiatric: psychotic episodes including delusions, hallucinations, and paranoid ideation, neuroleptic malignant syndrome (see WARNINGS), bradykinetic episodes ("on-off" phenomenon), confusion, agitation, dizziness, somnolence, dream abnormalities including nightmares, insomnia, paresthesia, headache, depression with or without development of suicidal tendencies, dementia, increased libido. Convulsions also have occurred; however, a causal relationship with carbidopa and levodopa has not been established.
Respiratory: dyspnea, upper respiratory infection
Skin: rash, increased sweating, alopecia, dark sweat
Urogenital: urinary tract infection, urinary frequency, dark urine
Laboratory Tests: decreased hemoglobin and hematocrit; abnormalities in alkaline phosphatase, SGOT (AST), SGPT (ALT), lactic dehydrogenase, bilirubin, blood urea nitrogen (BUN), Coombs test; elevated serum glucose; white blood cells, bacteria, and blood in the urine.
Other adverse reactions that have been reported with levodopa alone and with various carbidopa-levodopa formulations, and may occur with carbidopa and levodopa orally disintegrating tablets are:
Body as a Whole: abdominal pain and distress, fatigue
Cardiovascular: myocardial infarction
Gastrointestinal: gastrointestinal pain, dysphagia, sialorrhea, flatulence, bruxism, burning sensation of the tongue, heartburn, hiccups
Metabolic: edema, weight gain, weight loss
Musculoskeletal: leg pain
Nervous System/Psychiatric: ataxia, extrapyramidal disorder, falling, anxiety, gait abnormalities, nervousness, decreased mental acuity, memory impairment, disorientation, euphoria, blepharospasm (which may be taken as an early sign of excess dosage; consideration of dosage reduction may be made at this time), trismus, increased tremor, numbness, muscle twitching, activation of latent Horner's syndrome, peripheral neuropathy
Respiratory: pharyngeal pain, cough
Skin: malignant melanoma (see also CONTRAINDICATIONS), flushing
Special Senses: oculogyric crises, diplopia, blurred vision, dilated pupils
Urogenital: urinary retention, urinary incontinence, priapism
Miscellaneous: bizarre breathing patterns, faintness, hoarseness, malaise, hot flashes, sense of stimulation
Laboratory Tests: decreased white blood cell count and serum potassium; increased serum creatinine and uric acid; protein and glucose in urine.
Management of acute overdosage with carbidopa and levodopa orally disintegrating tablets is the same as management of acute overdosage with levodopa. Pyridoxine is not effective in reversing the actions of carbidopa and levodopa orally disintegrating tablets. General supportive measures should be employed, along with immediate gastric lavage. Intravenous fluids should be administered judiciously and an adequate airway maintained. Electrocardiographic monitoring should be instituted and the patient carefully observed for the development of arrhythmias; if required, appropriate anti-arrhythmic therapy should be given. The possibility that the patient may have taken other drugs as well as carbidopa and levodopa orally disintegrating tablets should be taken into consideration. To date, no experience has been reported with dialysis; hence, its value in overdosage is not known.
Based on studies in which high doses of levodopa and/or carbidopa were administered, a significant proportion of rats and mice given single oral doses of levodopa of approximately 1500 mg/kg to 2000 mg/kg are expected to die. A significant proportion of infant rats of both sexes are expected to die at a dose of 800 mg/kg. A significant proportion of rats are expected to die after treatment with similar doses of carbidopa. The addition of carbidopa in a 1:10 ratio with levodopa increases the dose at which a significant proportion of mice are expected to die to 3360 mg/kg.
Just prior to administration, GENTLY remove the tablet from the bottle with dry hands. IMMEDIATELY place the carbidopa and levodopa orally disintegrating tablet on top of the tongue where it will dissolve in seconds, then swallow with saliva. Administration with liquid is not necessary.
The optimum daily dosage of carbidopa and levodopa orally disintegrating tablets must be determined by careful titration in each patient. Carbidopa and levodopa orally disintegrating tablets are available in a 1:4 ratio of carbidopa to levodopa (carbidopa and levodopa orally disintegrating tablets 25 mg/100 mg) as well as 1:10 ratio (carbidopa and levodopa orally disintegrating tablets 25 mg/250 mg and carbidopa and levodopa orally disintegrating tablets 10 mg/100 mg). Tablets of the two ratios may be given separately or combined as needed to provide the optimum dosage.
Studies show that peripheral dopa decarboxylase is saturated by carbidopa at approximately 70 mg to 100 mg a day. Patients receiving less than this amount of carbidopa are more likely to experience nausea and vomiting.
Dosage is best initiated with one carbidopa and levodopa orally disintegrating tablet 25 mg/100 mg 3 times a day. This dosage schedule provides 75 mg of carbidopa per day. Dosage may be increased by one tablet every day or every other day, as necessary, until a dosage of eight carbidopa and levodopa orally disintegrating tablets 25 mg/100 mg a day is reached.
If carbidopa and levodopa orally disintegrating tablets 10 mg/100 mg are used, dosage may be initiated with one tablet 3 or 4 times a day. However, this will not provide an adequate amount of carbidopa for many patients. Dosage may be increased by one tablet every day or every other day until a total of eight tablets (two tablets q.i.d.) is reached.
Levodopa must be discontinued at least twelve hours before starting carbidopa and levodopa orally disintegrating tablets. A daily dosage of carbidopa and levodopa orally disintegrating tablets should be chosen that will provide approximately 25% of the previous levodopa dosage. Patients who are taking less than 1500 mg of levodopa a day should be started on one carbidopa and levodopa orally disintegrating tablet 25 mg/100 mg 3 or 4 times a day. The suggested starting dosage for most patients taking more than 1500 mg of levodopa is one carbidopa and levodopa orally disintegrating tablet 25 mg/250 mg 3 or 4 times a day.
Therapy should be individualized and adjusted according to the desired therapeutic response. At least 70 mg to 100 mg of carbidopa per day should be provided. When a greater proportion of carbidopa is required, one carbidopa and levodopa orally disintegrating tablet 25 mg/100 mg may be substituted for each carbidopa and levodopa orally disintegrating tablet 10 mg/100 mg. When more levodopa is required, carbidopa and levodopa orally disintegrating 25 mg/250 mg tablets should be substituted for carbidopa and levodopa orally disintegrating 25 mg/100 mg tablets or carbidopa and levodopa orally disintegrating 10 mg/100 mg tablets. If necessary, the dosage of carbidopa and levodopa orally disintegrating tablet 25 mg/250 mg tablets may be increased by one-half or one tablet every day or every other day to a maximum of eight tablets a day. Experience with total daily dosages of carbidopa greater than 200 mg is limited.
Because both therapeutic and adverse responses occur more rapidly with carbidopa and levodopa orally disintegrating tablets than with levodopa alone, patients should be monitored closely during the dose adjustment period. Specifically, involuntary movements will occur more rapidly with carbidopa and levodopa orally disintegrating tablets than with levodopa. The occurrence of involuntary movements may require dosage reduction. Blepharospasm may be a useful early sign of excess dosage in some patients.
Standard drugs for Parkinson's disease, other than levodopa without a decarboxylase inhibitor, may be used concomitantly while carbidopa and levodopa orally disintegrating tablets are being administered, although dosage adjustments may be required.
Sporadic cases of a symptom complex resembling Neuroleptic Malignant Syndrome (NMS) have been associated with dose reductions and withdrawal of carbidopa and levodopa. Patients should be observed carefully if abrupt reduction or discontinuation of carbidopa and levodopa orally disintegrating tablets is required, especially if the patient is receiving neuroleptics (See WARNINGS).
If general anesthesia is required, carbidopa and levodopa orally disintegrating tablets may be continued as long as the patient is permitted to take fluids and medication by mouth. If therapy is interrupted temporarily, the patient should be observed for symptoms resembling NMS, and the usual daily dosage may be administered as soon as the patient is able to take oral medication.
Carbidopa and Levodopa Orally Disintegrating Tablets, USP are available containing 10 mg or 25 mg of carbidopa, USP, with 100 mg or 250 mg of levodopa, USP providing the following available combinations: 10 mg/100 mg, 25 mg/100 mg or 25 mg/250 mg.
The 10 mg/100 mg orally disintegrating tablets are green, round, scored and debossed with M above the score and C51 below the score on one side of the tablet and blank on the other side. They are available as follows:
NDC 0378-5051-01
bottles of 100 tablets
The 25 mg/100 mg orally disintegrating tablets are blue, round, scored and debossed with M above the score and C52 below the score on one side of the tablet and blank on the other side. They are available as follows:
NDC 0378-5052-01
bottles of 100 tablets
The 25 mg/250 mg orally disintegrating tablets are green, round, scored and debossed with M above the score and C53 below the score on one side of the tablet and blank on the other side. They are available as follows:
NDC 0378-5053-01
bottles of 100 tablets
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
Protect from moisture and light.
Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505
Revised: 9/2016
CLODT:R3
NDC 0378-5051-01
Carbidopa and
Levodopa
Orally Disintegrating
Tablets, USP
10 mg/100 mg
Phenylketonurics: Contains phenylalanine
3.37 mg per tablet.
Rx only 100 Tablets
Each tablet contains:
Carbidopa, USP 10 mg
Levodopa, USP 100 mg
Dispense in a tight, light-resistant
container as defined in the USP
using a child-resistant closure.
Keep container tightly closed.
Keep this and all medication
out of the reach of children.
Store at 20° to 25°C (68° to 77°F).
[See USP Controlled Room
Temperature.]
Protect from moisture and light.
Do not remove tablets from the bottle
until immediately before use.
Usual Dosage: See accompanying
prescribing information.
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
Mylan.com
RM5051A2
NDC 0378-5052-01
Carbidopa and
Levodopa
Orally Disintegrating
Tablets, USP
25 mg/100 mg
Phenylketonurics: Contains phenylalanine
3.37 mg per tablet.
Rx only 100 Tablets
Each tablet contains:
Carbidopa, USP 25 mg
Levodopa, USP 100 mg
Dispense in a tight, light-resistant
container as defined in the USP
using a child-resistant closure.
Keep container tightly closed.
Keep this and all medication
out of the reach of children.
Store at 20° to 25°C (68° to 77°F).
[See USP Controlled Room
Temperature.]
Protect from moisture and light.
Do not remove tablets from the bottle
until immediately before use.
Usual Dosage: See accompanying
prescribing information.
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
Mylan.com
RM5052A2
NDC 0378-5053-01
Carbidopa and
Levodopa
Orally Disintegrating
Tablets, USP
25 mg/250 mg
Phenylketonurics: Contains phenylalanine
8.42 mg per tablet.
Rx only 100 Tablets
Each tablet contains:
Carbidopa, USP 25 mg
Levodopa, USP 250 mg
Dispense in a tight, light-resistant
container as defined in the USP
using a child-resistant closure.
Keep container tightly closed.
Keep this and all medication
out of the reach of children.
Store at 20° to 25°C (68° to 77°F).
[See USP Controlled Room
Temperature.]
Protect from moisture and light.
Do not remove tablets from the bottle
until immediately before use.
Usual Dosage: See accompanying
prescribing information.
This container is not intended for dispensing
for household use.
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
RM5053A2
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0378-5051-01 | EA - Each | 0378-5051 | 4f66a335-16bd-483d-88d3-10fa8dbb413e | 1 | 2012-07-24 |
| 0378-5052-01 | EA - Each | 0378-5052 | 87611a8b-d3f2-4342-9008-05d2694927d5 | 1 | 2012-07-24 |
| 0378-5053-01 | EA - Each | 0378-5053 | 48aa30aa-740f-4340-9f1b-c84f6fb5526e | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CARBIDOPA | ACTIVE INGREDIENT | MNX7R8C5VO | 4 | |
| LEVODOPA | ACTIVE INGREDIENT | 46627O600J | 4 | |
| CARBIDOPA ANHYDROUS | ACTIVE MOIETY | KR87B45RGH | 4 | |
| LEVODOPA | ACTIVE MOIETY | 46627O600J | 4 | |
| ASPARTAME | INACTIVE INGREDIENT | Z0H242BBR1 | 4 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 4 | |
| CROSPOVIDONE | INACTIVE INGREDIENT | 68401960MK | 4 | |
| D&C YELLOW NO. 10 | INACTIVE INGREDIENT | 35SW5USQ3G | 4 | |
| FD&C BLUE NO. 1 | INACTIVE INGREDIENT | H3R47K3TBD | 4 | |
| MANNITOL | INACTIVE INGREDIENT | 3OWL53L36A | 4 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 4 | |
| SODIUM STEARYL FUMARATE | INACTIVE INGREDIENT | 7CV7WJK4UI | 4 | |
| SORBITOL | INACTIVE INGREDIENT | 506T60A25R | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0378-5051 | 0378-5051-01 |
| 0378-5052 | 0378-5052-01 |
| 0378-5053 | 0378-5053-01 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 336 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | PASTE, DENTIFRICE / DENTAL | 14 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION / INTRA-ARTICULAR | 45 %w/v | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | SUSPENSION / ORAL | 1600 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | TABLET, FILM COATED / ORAL | 20 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | GUM, CHEWING / ORAL | 6168 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | NA | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | GEL / DENTAL | NA | ||
| SORBITOL | SORBITOL | 506T60A25R | TABLET, FILM COATED / ORAL | 5 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | POWDER, FOR SUSPENSION / ORAL | 420 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | TABLET, FOR SUSPENSION / ORAL | 15 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, DELAYED RELEASE / ORAL | 1190 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 1568 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | POWDER / ORAL | 36000 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SUSPENSION / OPHTHALMIC | 9 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | TABLET, ORALLY DISINTEGRATING / ORAL | 180 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | CAPSULE, DELAYED RELEASE / ORAL | 1 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | SUSPENSION / ORAL | 23 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | GEL / TOPICAL | NA | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, COATED / ORAL | 177.7 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | LIQUID / ORAL | NA | ||
| SORBITOL | SORBITOL | 506T60A25R | POWDER, FOR SUSPENSION / ORAL | 12000 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, SOLUBLE / ORAL | 2 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | EMULSION / TOPICAL | 7 %w/w | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | CAPSULE, LIQUID FILLED / ORAL | 1.51 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | SHAMPOO / TOPICAL | NA | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION / INTRAMUSCULAR | 106.6 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CONCENTRATE / ORAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FOR SUSPENSION / ORAL | 220 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | POWDER / ORAL | 48 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION / INTRAMUSCULAR | NA | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SOLUTION, GEL FORMING / DROPS / OPHTHALMIC | 4 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | LOZENGE / ORAL | 120 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 78 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CAPSULE, EXTENDED RELEASE / ORAL | 1 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | TABLET, DELAYED RELEASE / ORAL | 0.01 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / RESPIRATORY (INHALATION) | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SUSPENSION / ORAL | 200 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, DELAYED RELEASE / ORAL | 3.2 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 1.04 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 181 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SUSPENSION/ DROPS / OPHTHALMIC | 3.3 %w/v | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION / INTRASYNOVIAL | 45 %w/v | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, ORALLY DISINTEGRATING / ORAL | 68 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / ORAL | 300 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | TABLET, FILM COATED / ORAL | 120 mg | ||
| SODIUM STEARYL FUMARATE | SODIUM STEARYL FUMARATE | 7CV7WJK4UI | TABLET, CHEWABLE / ORAL | 28 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | TABLET, DELAYED RELEASE / ORAL | 1.9 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | SOLUTION / ORAL | 8 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | TABLET, CHEWABLE / ORAL | 195 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION / SUBCUTANEOUS | 4.7 %w/v | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / SUBLINGUAL | 10 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | PASTE / DENTAL | 34 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION / INTRAVENOUS | 1276 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | SYRUP / ORAL | 4 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | CAPSULE / ORAL | 20 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | CONCENTRATE / ORAL | 600 mg/1ml | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | POWDER, FOR SOLUTION / ORAL | 233 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SUSPENSION / INTRAMUSCULAR | 164 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A078893-001 | CARBIDOPA AND LEVODOPA | CARBIDOPA; LEVODOPA | 10MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | AB | 2008-09-18 | |
| A078893-002 | CARBIDOPA AND LEVODOPA | CARBIDOPA; LEVODOPA | 25MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | AB | 2008-09-18 | |
| A078893-003 | CARBIDOPA AND LEVODOPA | CARBIDOPA; LEVODOPA | 25MG;250MG | TABLET, ORALLY DISINTEGRATING / ORAL | AB | 2008-09-18 |
| Application-product | TE code |
|---|---|
| A078893-001 | AB |
| A078893-002 | AB |
| A078893-003 | AB |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A078893-001 | CARBIDOPA AND LEVODOPA | 10MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | AB | 2008-09-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A078893-002 | CARBIDOPA AND LEVODOPA | 25MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | AB | 2008-09-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A078893-003 | CARBIDOPA AND LEVODOPA | 25MG;250MG | TABLET, ORALLY DISINTEGRATING / ORAL | AB | 2008-09-18 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A078893-001 | CARBIDOPA AND LEVODOPA | 10MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | AB | 2008-09-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A078893-002 | CARBIDOPA AND LEVODOPA | 25MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | AB | 2008-09-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A078893-003 | CARBIDOPA AND LEVODOPA | 25MG;250MG | TABLET, ORALLY DISINTEGRATING / ORAL | AB | 2008-09-18 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A078893-001 | CARBIDOPA AND LEVODOPA | 10MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | AB | 2008-09-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A078893-002 | CARBIDOPA AND LEVODOPA | 25MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | AB | 2008-09-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A078893-003 | CARBIDOPA AND LEVODOPA | 25MG;250MG | TABLET, ORALLY DISINTEGRATING / ORAL | AB | 2008-09-18 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A078893-001 | CARBIDOPA AND LEVODOPA | 10MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | AB | 2008-09-18 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A078893-002 | CARBIDOPA AND LEVODOPA | 25MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | AB | 2008-09-18 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A078893-003 | CARBIDOPA AND LEVODOPA | 25MG;250MG | TABLET, ORALLY DISINTEGRATING / ORAL | AB | 2008-09-18 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A078893-001 | CARBIDOPA AND LEVODOPA | 10MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A078893-002 | CARBIDOPA AND LEVODOPA | 25MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A078893-003 | CARBIDOPA AND LEVODOPA | 25MG;250MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A078893-001 | CARBIDOPA AND LEVODOPA | 10MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A078893-002 | CARBIDOPA AND LEVODOPA | 25MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A078893-003 | CARBIDOPA AND LEVODOPA | 25MG;250MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A078893-001 | CARBIDOPA AND LEVODOPA | 10MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A078893-002 | CARBIDOPA AND LEVODOPA | 25MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A078893-003 | CARBIDOPA AND LEVODOPA | 25MG;250MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A078893-001 | CARBIDOPA AND LEVODOPA | 10MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A078893-002 | CARBIDOPA AND LEVODOPA | 25MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A078893-003 | CARBIDOPA AND LEVODOPA | 25MG;250MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A078893-001 | CARBIDOPA AND LEVODOPA | 10MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | 2680178bc6a6… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A078893-002 | CARBIDOPA AND LEVODOPA | 25MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | 2680178bc6a6… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A078893-003 | CARBIDOPA AND LEVODOPA | 25MG;250MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A078893-001 | CARBIDOPA AND LEVODOPA | 10MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | 5bbf6a4d5a75… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A078893-002 | CARBIDOPA AND LEVODOPA | 25MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | 5bbf6a4d5a75… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A078893-003 | CARBIDOPA AND LEVODOPA | 25MG;250MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A078893-001 | CARBIDOPA AND LEVODOPA | 10MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | d8e5a09893c0… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A078893-002 | CARBIDOPA AND LEVODOPA | 25MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | d8e5a09893c0… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A078893-003 | CARBIDOPA AND LEVODOPA | 25MG;250MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A078893-001 | CARBIDOPA AND LEVODOPA | 10MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | d06236e962d9… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A078893-002 | CARBIDOPA AND LEVODOPA | 25MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | d06236e962d9… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A078893-003 | CARBIDOPA AND LEVODOPA | 25MG;250MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A078893-001 | CARBIDOPA AND LEVODOPA | 10MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | 79d66fd596c7… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A078893-002 | CARBIDOPA AND LEVODOPA | 25MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | 79d66fd596c7… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A078893-003 | CARBIDOPA AND LEVODOPA | 25MG;250MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A078893-001 | CARBIDOPA AND LEVODOPA | 10MG;100MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2008-09-18 | 301d65b070ca… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A078893-001 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A078893-002 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A078893-003 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A078893-001 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A078893-002 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A078893-003 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A078893-001 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A078893-002 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A078893-003 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A078893-001 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A078893-002 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A078893-003 | AB | 1 | 31067a03dcf5… |
| 2019-12-13 00:20 UTC | 2019-12 | A078893-001 | AB | 1 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | A078893-002 | AB | 1 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | A078893-003 | AB | 1 | 74a2ff9319b5… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A078893-001 | AB | 1 | 87673890dc5c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A078893-002 | AB | 1 | 87673890dc5c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A078893-003 | AB | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A078893-001 | AB | 1 | 5aa47cf7b7d7… |
| 2021-03-12 10:30 UTC | 2021-03 | A078893-002 | AB | 1 | 5aa47cf7b7d7… |
| 2021-03-12 10:30 UTC | 2021-03 | A078893-003 | AB | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A078893-001 | AB | 1 | 8869cabd3fbd… |
| 2020-12-22 03:56 UTC | 2020-12 | A078893-002 | AB | 1 | 8869cabd3fbd… |
| 2020-12-22 03:56 UTC | 2020-12 | A078893-003 | AB | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A078893-001 | AB | 1 | c0c555d07b60… |
| 2020-11-12 02:37 UTC | 2020-11 | A078893-002 | AB | 1 | c0c555d07b60… |
| 2020-11-12 02:37 UTC | 2020-11 | A078893-003 | AB | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A078893-001 | AB | 1 | 3f01610625f2… |
| 2019-12-14 00:12 UTC | 2019-12 | A078893-002 | AB | 1 | 3f01610625f2… |
| 2019-12-14 00:12 UTC | 2019-12 | A078893-003 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A078893-001 | AB | 1 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | A078893-002 | AB | 1 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | A078893-003 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A078893-001 | AB | 1 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | A078893-002 | AB | 1 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | A078893-003 | AB | 1 | ea99ee380514… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A078893-001 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A078893-002 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A078893-003 | AB | 1 | a50c72e98297… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 9edb6ea2-d6b6-450f-a5c1-c52c6ad7e49e | f1a334d2-129c-49f9-bd29-6bb0838085fe | 2016-09-14 | Warnings, Adverse reactions | f1a334d2-129c-49f9-bd29-6bb0838085fe |
Adverse event summaries are temporarily unavailable. Other product information remains available.